Cargando…
Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review
Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of liver abnormalities, from benign steatosis to nonalcoholic steatohepatitis (NASH). Because of their antioxidant capabilities, CeNPs have sparked a lot of interest in biological applications. This review evaluated the effectiveness of C...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648767/ https://www.ncbi.nlm.nih.gov/pubmed/37958712 http://dx.doi.org/10.3390/ijms242115728 |
_version_ | 1785135416816435200 |
---|---|
author | Sandoval, Cristian Reyes, Carolina Rosas, Pamela Godoy, Karina Souza-Mello, Vanessa Farías, Jorge |
author_facet | Sandoval, Cristian Reyes, Carolina Rosas, Pamela Godoy, Karina Souza-Mello, Vanessa Farías, Jorge |
author_sort | Sandoval, Cristian |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of liver abnormalities, from benign steatosis to nonalcoholic steatohepatitis (NASH). Because of their antioxidant capabilities, CeNPs have sparked a lot of interest in biological applications. This review evaluated the effectiveness of CeNPs in NAFLD evolution through in vivo and in vitro studies. Databases such as MEDLINE, EMBASE, Scopus, and Web of Science were looked for studies published between 2012 and June 2023. Quality was evaluated using PRISMA guidelines. We looked at a total of nine primary studies in English carried out using healthy participants or HepG2 or LX2 cells. Quantitative data such as blood chemical markers, lipid peroxidation, and oxidative status were obtained from the studies. Our findings indicate that NPs are a possible option to make medications safer and more effective. In fact, CeNPs have been demonstrated to decrease total saturated fatty acids and foam cell production (steatosis), reactive oxygen species production and TNF-α (necrosis), and vacuolization in hepatic tissue when used to treat NAFLD. Thus, CeNP treatment may be considered promising for liver illnesses. However, limitations such as the variation in durations between studies and the utilization of diverse models to elucidate the etiology of NAFLD must be considered. Future studies must include standardized NAFLD models. |
format | Online Article Text |
id | pubmed-10648767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106487672023-10-29 Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review Sandoval, Cristian Reyes, Carolina Rosas, Pamela Godoy, Karina Souza-Mello, Vanessa Farías, Jorge Int J Mol Sci Review Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of liver abnormalities, from benign steatosis to nonalcoholic steatohepatitis (NASH). Because of their antioxidant capabilities, CeNPs have sparked a lot of interest in biological applications. This review evaluated the effectiveness of CeNPs in NAFLD evolution through in vivo and in vitro studies. Databases such as MEDLINE, EMBASE, Scopus, and Web of Science were looked for studies published between 2012 and June 2023. Quality was evaluated using PRISMA guidelines. We looked at a total of nine primary studies in English carried out using healthy participants or HepG2 or LX2 cells. Quantitative data such as blood chemical markers, lipid peroxidation, and oxidative status were obtained from the studies. Our findings indicate that NPs are a possible option to make medications safer and more effective. In fact, CeNPs have been demonstrated to decrease total saturated fatty acids and foam cell production (steatosis), reactive oxygen species production and TNF-α (necrosis), and vacuolization in hepatic tissue when used to treat NAFLD. Thus, CeNP treatment may be considered promising for liver illnesses. However, limitations such as the variation in durations between studies and the utilization of diverse models to elucidate the etiology of NAFLD must be considered. Future studies must include standardized NAFLD models. MDPI 2023-10-29 /pmc/articles/PMC10648767/ /pubmed/37958712 http://dx.doi.org/10.3390/ijms242115728 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sandoval, Cristian Reyes, Carolina Rosas, Pamela Godoy, Karina Souza-Mello, Vanessa Farías, Jorge Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review |
title | Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review |
title_full | Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review |
title_fullStr | Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review |
title_full_unstemmed | Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review |
title_short | Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review |
title_sort | effectiveness of cerium oxide nanoparticles in non-alcoholic fatty liver disease evolution using in vivo and in vitro studies: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648767/ https://www.ncbi.nlm.nih.gov/pubmed/37958712 http://dx.doi.org/10.3390/ijms242115728 |
work_keys_str_mv | AT sandovalcristian effectivenessofceriumoxidenanoparticlesinnonalcoholicfattyliverdiseaseevolutionusinginvivoandinvitrostudiesasystematicreview AT reyescarolina effectivenessofceriumoxidenanoparticlesinnonalcoholicfattyliverdiseaseevolutionusinginvivoandinvitrostudiesasystematicreview AT rosaspamela effectivenessofceriumoxidenanoparticlesinnonalcoholicfattyliverdiseaseevolutionusinginvivoandinvitrostudiesasystematicreview AT godoykarina effectivenessofceriumoxidenanoparticlesinnonalcoholicfattyliverdiseaseevolutionusinginvivoandinvitrostudiesasystematicreview AT souzamellovanessa effectivenessofceriumoxidenanoparticlesinnonalcoholicfattyliverdiseaseevolutionusinginvivoandinvitrostudiesasystematicreview AT fariasjorge effectivenessofceriumoxidenanoparticlesinnonalcoholicfattyliverdiseaseevolutionusinginvivoandinvitrostudiesasystematicreview |